<?xml version='1.0' encoding='utf-8'?>
<document id="20691589"><sentence text="Design, synthesis, and biological evaluation of new monoamine reuptake inhibitors with potential therapeutic utility in depression and pain."><entity charOffset="52-61" id="DDI-PubMed.20691589.s1.e0" text="monoamine" /></sentence><sentence text="Two new series of monoamine triple reuptake inhibitors (TRIs) have been discovered through scaffold homologation of our recently reported series of 3,3-disubstituted pyrrolidine TRIs"><entity charOffset="18-27" id="DDI-PubMed.20691589.s2.e0" text="monoamine" /><entity charOffset="148-182" id="DDI-PubMed.20691589.s2.e1" text="3,3-disubstituted pyrrolidine TRIs" /><pair ddi="false" e1="DDI-PubMed.20691589.s2.e0" e2="DDI-PubMed.20691589.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20691589.s2.e0" e2="DDI-PubMed.20691589.s2.e1" /></sentence><sentence text=" The regioisomeric 2- and 3-ketopyrrolidines demonstrated high levels of potency against all three monoamine transporters as well as good human in vitro stability, low drug-drug interaction potential and a decreased propensity for hERG channel binding"><entity charOffset="19-44" id="DDI-PubMed.20691589.s3.e0" text="2- and 3-ketopyrrolidines" /><entity charOffset="99-108" id="DDI-PubMed.20691589.s3.e1" text="monoamine" /><pair ddi="false" e1="DDI-PubMed.20691589.s3.e0" e2="DDI-PubMed.20691589.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20691589.s3.e0" e2="DDI-PubMed.20691589.s3.e1" /></sentence><sentence text=" Representative compounds from these series displayed good in vivo pharmacokinetics and high monoamine receptor occupancies which are indicators of good brain penetration"><entity charOffset="93-102" id="DDI-PubMed.20691589.s4.e0" text="monoamine" /></sentence><sentence text="" /></document>